Add Formweb to your mobile device
Approved Formulary
Search results for:
cloNIDine
cloNIDine
Brand names: Catapres, Catapres-TTS-1, Catapres-TTS-2, Catapres-TTS-3, Duraclon
| Form | Strength |
|---|---|
| FILM, EXTENDED RELEASE, TRANSDERMAL | 0.1 mg/24 hr; 0.2 mg/24 hr; 0.3 mg/24 hr |
| SOLUTION, INTRATHECAL | 1 mg/10 mL |
| TABLET, ORAL | 0.1 mg |
Display Central alpha-Agonists Class:
242400
Medication comments:
| 2023 American Geriatrics Society Beers Criteria® for potentially inappropriate medication use in older adults. | |
|---|---|
| Medication: | cloNIDine (Catapres) |
| Criteria 1: Potentially inappropriate medication use in older adults. (Table 2) | |
| Drug(s) | central alpha-agonists for the treatment of hypertension |
| Rationale | High risk of adverse CNS effects; may cause bradycardia and orthostatic hypotension; not recommended as routine treatment for hypertension. |
| Recommendation | Avoid cloNIDine as first-line treatment for hypertension. |
| Quality of evidence: Low, Strength of Recommendation: Strong | |
Last updated: Sep. 18, 2025
- Black Box Warnings Epidural cloNIDine
- Look-Alike/Sound-Alike cloNIDine confused with clonazePAM, cloZAPine, KlonoPIN